论文部分内容阅读
目的探讨脑钠肽监测对中、重度心力衰竭患者β1受体阻滞剂应用的指导作用。方法分67例中、重度心衰患者为2组,实验组通过监测BNP水平指导β1受体阻滞剂使用,对照组通过临床表现指导用药,比较两组效果。结果实验组美托洛尔启用时间短于对照组,差异有统计学意义(t=2.02,P﹤0.05)。实验组美托洛尔平均用药量大于对照组,差异有统计学意义(t=2.39,P﹤0.05)。两组患者心衰复发率差异无统计学意义(P﹥0.05)。结论监测中、重度心衰患者BNP水平对指导β1受体阻滞剂的使用有较高的临床价值。
Objective To investigate the effect of BNP monitoring on β1 blockers in patients with moderate and severe heart failure. Methods Sixty-seven patients with moderate and severe heart failure were divided into two groups. The experimental group was given β1-adrenergic receptor blocker by monitoring the level of BNP. The control group was guided by clinical manifestations to compare the effects of the two groups. Results The activation time of metoprolol in experimental group was shorter than that in control group (t = 2.02, P <0.05). The average dosage of metoprolol in the experimental group was larger than that in the control group, with significant difference (t = 2.39, P <0.05). There was no significant difference in the relapse rate of heart failure between the two groups (P> 0.05). Conclusion The monitoring of BNP levels in patients with moderate and severe heart failure has a higher clinical value of the use of β1-blocker.